Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The UK company buys IRDx for $1bn.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
